Genomics of Inflammation and Immunity

We use high-throughput genetic and genomic screens, plus immunological assays, to identify drug targets for immune-mediated disease, with a particular focus on primary sclerosing cholangitis (PSC) and inflammatory bowel disease (IBD).

What we are doing


We perform large scale screening of human genomes to identify genetic variants influencing immune-mediated diseases (e.g. IBD and PSC) and immune responses in health (e.g. following vaccination).


We use sequencing (e.g RNA-seq and ATAC-seq) to identify regulatory elements in disease relevant cells, and then map the genetic variants that influence these.


In our wet lab we perform high-throughput screens (e.g. CRISPR screens) and cellular assays to understand the biological mechanisms via which disease-associated variants mitigate risk.